Summary & Overview
HCPCS J7330: Autologous Cultured Chondrocytes, Implant
HCPCS Level II code J7330 identifies an autologous cultured chondrocytes implant, a regenerative orthopedic therapy that uses a patient’s own cartilage cells to repair focal articular cartilage defects. The code is clinically significant due to the specialized manufacturing, surgical implantation process, and implications for coverage policy and utilization management across payers. Nationally, this therapy factors into discussions about advanced biologic implants, surgical outcomes, and cost-effectiveness for focal cartilage repair.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, common payer approaches to coverage and prior authorization, and service-line considerations for hospitals and ambulatory surgical centers. The publication summarizes expected sites of service, clinical context for use in orthopedic surgery, and common billing modifiers and claim considerations when data are available. Benchmarks, policy updates, and payer-specific guidance are presented where available; if payer-specific details are not provided, the section will note: "Data not available in the input."
This summary is written for a national audience seeking concise guidance on how HCPCS Level II code J7330 fits into clinical practice, coding workflows, and payer interactions for advanced cartilage repair procedures.
Billing Code Overview
HCPCS Level II code J7330 denotes autologous cultured chondrocytes, implant. This code represents a biologic implant procedure using a patient’s own cultured cartilage cells to repair focal cartilage defects. The service type is an implantation of autologous cultured chondrocytes, a specialized orthopedic regenerative therapy.
Typical site of service for this procedure is an inpatient or outpatient hospital setting or ambulatory surgical center, where surgical implantation and required perioperative care are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 25–45-year-old active adult with a focal, full-thickness articular cartilage defect of the femoral condyle or trochlea of the knee after failed conservative management and persistent mechanical symptoms. The patient has persistent joint pain, swelling, and activity limitation despite physical therapy, NSAIDs, and possibly prior microfracture or chondroplasty. Imaging includes MRI demonstrating a symptomatic focal chondral defect; arthroscopy confirms size and depth suitable for autologous chondrocyte implantation.
The clinical workflow begins with an initial orthopedic evaluation, history and physical exam, and MRI. If candidate criteria are met, the patient undergoes arthroscopic biopsy of healthy cartilage for chondrocyte harvest. The harvested cartilage is sent to a cell-culture laboratory for expansion (weeks to months). Once adequate autologous cultured chondrocytes are available, the patient returns for implantation via open or arthroscopic procedure: defect debridement, preparation of the recipient bed, and implantation of the cultured chondrocyte product under a periosteal patch or scaffold. Postoperative care includes protected weightbearing, structured rehabilitation, serial clinical assessments, and follow-up imaging to monitor repair tissue maturation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity substantially exceeds the typical service for the implantation procedure. |